MedTrace Logo

Thrombo-Elastography Guided Management of ECMO

NCT04268940 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 61

Last updated 2026-01-16

No results posted yet for this study

Summary

Anticoagulation and coagulation management during ECMO is a challenge. Bleeding and clotting are major sources of morbidity and mortality. The currently used strategies are of poor evidence. This observational study wants to evaluate the use of automated thromboelastography (TEG 6s) to guide the management of coagulation and anticoagulation in patients supported by ECMO

Conditions

  • Extracorporeal Circulation of Blood; Thrombocytopenia

Interventions

DIAGNOSTIC_TEST

Thromboelastography

Thromboelastography (TEG 6s, global hemostasis cartridge) will be performed before ECMO insertion and at different time-points during the course of ECMO. In parallel a full coagulation work-up (aPTT, prothrombin time \[PT\], anti-Xa, activated clotting time\[ACT\], platelets count, d-dimers, von Willebrand panel and fibrinogen) will be measured simultaneously with each TEG.

Sponsors & Collaborators

  • The Physicians' Services Incorporated Foundation

    collaborator OTHER

  • Damian Ratano

    lead OTHER

Principal Investigators

  • Damian Ratano, MD · University Health Network, Toronto

  • Eddy Fan, MD, PhD · University Health Network, Toronto

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-03
Primary Completion
2021-06-04
Completion
2021-06-04

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04268940 on ClinicalTrials.gov